Tens of thousands of NHS cancer patients throughout England are set to benefit from a transformative shift to their care pathway, as a faster injectable form of the world’s best-selling cancer drug is now available on the NHS. Keytruda, an immunotherapeutic agent already used to fight 14 distinct forms of cancer, has been delivered through intravenous drip for nearly a decade—a process that could take over an hour in hospital. The new injectable version, nonetheless, can be administered in just minutes, set to substantially cut patients’ time spent in hospital chairs and free up crucial NHS capacity. Initial patients, including 86-year-old Shirley Xerxes from Hertfordshire, have already experienced the transformation firsthand.
A transformative change in cancer care provision
The rollout of injectable Keytruda represents a significant change in operations for NHS cancer centres across England. Where patients previously required prolonged hospital visits for IV infusions lasting over an hour, the new injection method shortens the whole process to just 1-2 minutes, depending on the treatment schedule. This operational simplification is especially beneficial given that roughly 14,000 cancer patients in England begin Keytruda treatment annually, with the vast majority projected to switch to the injectable form. The efficiency gains extend beyond patient convenience, allowing hospital pharmacy teams from the time-consuming task of preparing sterile infusion bags and enabling clinical staff to dedicate their time more effectively across busy cancer centres.
NHS England’s chief clinical director for cancer, Professor Peter Johnson, has underscored the multiple advantages of this shift. The switch to a standard, rapid injection not only strengthens the patient satisfaction but also improves clinical workflows and resource allocation. For patients like Shirley Xerxes, the practical impact is substantial—what once required a considerable amount of her day now takes mere minutes, allowing her to reclaim time for personal interests and sustain her standard of living between treatments. This represents the third injectable immunotherapy option now offered by the NHS, after the rollout of Opdivo in injectable format at select hospitals in the preceding year, pointing to a wider shift towards patient-centred cancer care that is efficient.
- Injection given every three weeks as a one-minute administration
- Alternative six-weekly dosing offered as two-minute injection
- Around 14,000 patients per year qualified for therapy
- Active against 14 distinct cancer varieties including lung and breast
How immune-based therapy combats cancer
Keytruda is part of a category of drugs known as immunotherapy, which leverages the body’s own immune system to identify and eliminate cancer cells. Cancer cells are particularly cunning—they generate proteins that effectively send a “stop signal” to immune cells, preventing the body from launching an effective defence. Scientists frequently characterise this mechanism as cancer concealed by an “invisibility cloak”, enabling malignant cells to escape detection and proliferate unchecked. Immunotherapy drugs like Keytruda function by blocking these deceptive signals, essentially stripping away the cloak and rendering cancer cells visible to the immune system once again.
The breakthrough in comprehending this mechanism proved so substantial that it secured two scientists—James Allison and Tasuku Honjo—the Nobel Prize for Physiology or Medicine in 2018. Keytruda was one of the first immunotherapy drugs approved for clinical use, originally for melanoma before being expanded to address numerous additional cancers. Today, it represents the world’s best-selling prescription medicine, with worldwide revenue reaching £22 billion in 2025. This remarkable commercial success reflects both the clinical efficacy of the drug and the growing acknowledgement of immunotherapy as a revolutionary approach to cancer care.
The research behind overcoming cancer’s defences
When cancer cells work to inhibit immune activity through their protective proteins, Keytruda acts by disrupting these suppressive pathways. This allows T-cells—the body’s first-line immune fighters—to recognise cancer cells more readily and execute an effective counterattack. By essentially removing the molecular concealment mechanism, the drug restores the immune system’s inherent capacity to recognise and destroy malignant cells, delivering patients a more focused and potentially less harmful treatment option than traditional chemotherapy approaches.
Genuine patient feedback with the latest treatment
Shirley Xerxes, an 86-year-old from St Albans in Hertfordshire, was amongst the earliest NHS patients to benefit from the injectable Keytruda at the Mount Vernon Cancer Centre near Watford. Her experience illustrates the significant change this latest version offers. Where she previously spent over an hour in a hospital chair undergoing intravenous infusion, the injection now takes only minutes. “It’s made such a difference and gives me greater opportunity to enjoy life, including enjoying more gardening time,” Shirley discussed her treatment experience, emphasising how the reduced hospital time results in improved quality of life.
For numerous NHS cancer patients across England, the move away from drip-based administration to quick injection represents a major improvement in quality of life. The efficient process eliminates the lengthy wait times and discomfort associated with prolonged infusions, letting patients resume their everyday routines much faster. With approximately 14,000 cancer patients in England beginning Keytruda treatment annually, the majority are projected to switch to this faster injectable version. This broad uptake is set not only to enhance individual patient experiences but also to release precious NHS facility resources and personnel hours, delivering mutual benefits for both patients and the health service.
- Treatment duration reduced from over one hour to only a few minutes per appointment
- Injections administered every three weeks as single-minute treatments or at six-weekly intervals as two-minute doses
- Patients gain significantly more time to pursue daily activities and hobbies outside hospital
Broader implications for NHS resources and future healthcare
The launch of injectable Keytruda represents a major procedural change for NHS cancer services. By shortening treatment time from over an hour to only minutes, hospitals can dramatically increase patient throughput without increasing facilities or workforce capacity. This productivity improvement allows oncology departments to accommodate more patients within available clinic time, ultimately decreasing wait periods across the entire cancer treatment pathway. Furthermore, the streamlined preparation procedure—removing the requirement for pharmacy teams to prepare individual infusion bags under controlled environments—improves efficiency and lowers the chance of preparation errors, improving safety and efficiency across NHS trusts.
Beyond immediate operational benefits, this development signals a broader shift towards patient-centred cancer care within the NHS. The time savings achieved through injectable administration could be redirected towards other aspects of patient support, such as counselling, nutritional guidance, and survivorship programmes. NHS England’s commitment to rolling out this treatment across the country demonstrates the organisation’s engagement with clinical innovation and its determination to deliver world-class cancer services. As more immunotherapy drugs become available in injectable form, the NHS is positioned to position itself as a leader in contemporary, streamlined cancer treatment delivery.
Opportunity for community-led oncology services
The rapid delivery speed of injectable Keytruda presents compelling possibilities for decentralising cancer treatment beyond traditional hospital environments. Community health centres and GP practices having access to appropriate facilities could potentially provide these treatments, moving care closer to patients’ homes and decreasing travel demands. This transition to community-centred care could turn out to be particularly advantageous for older patients and those residing in countryside locations, while simultaneously relieving strain on hospital cancer departments and enabling them to direct attention on more complicated cases needing specialist supervision.
- Treatment could be administered in local health centres and primary care practices with adequate facilities
- Decreased travel requirements for patients, notably those in isolated or countryside areas
- Hospital oncology departments freed to focus on intricate cases demanding specialist expertise
Market forces and patent-related factors
Keytruda’s conversion to injectable form reaches a critical juncture in the international pharmaceutical sector. With annual revenues totalling £22 billion internationally, the drug constitutes the world’s best-selling prescription medicine, a position it has maintained through ongoing clinical advancement and regulatory endorsements across multiple cancer indications. The transition to injectable administration strengthens its competitive edge by addressing a significant pain point for patients—prolonged clinical visits—whilst simultaneously improving operational efficiency for health services. This development underscores how pharmaceutical companies are increasingly responding to real-world patient needs, not merely expanding their product portfolios but fundamentally reshaping the treatment experience.
The introduction of injectable Keytruda also has implications for the NHS’s long-term drug procurement strategy and financial management. As the patent landscape evolves and biosimilar formulations of pembrolizumab emerge in the coming years, the injectable formulation may affect negotiation discussions and competitive dynamics. NHS England’s quick implementation of this innovative administration route positions the healthcare system advantageously, possibly obtaining priority access and negotiating leverage with drug makers. The efficient administration also decreases healthcare expenses separate from the drug price itself, such as reduced nursing time, briefer clinical visits, and reduced facility demands—elements that support the cost-benefit argument for widespread rollout across England’s cancer centres.